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Abstract 28 
We examined the efficacy and acceptability of non-invasive brain stimulation in adult 29 
unipolar and bipolar depression. Randomised sham-controlled trials of transcranial direct 30 
current stimulation (tDCS), transcranial magnetic stimulation (TMS) and theta-burst 31 
stimulation (TBS), without co-initiation of another treatment, were included. We analysed 32 
effects on response, remission, all-cause discontinuation rates and continuous depression 33 
severity measures. Fifty-six studies met our criteria for inclusion (N = 3,058, mean age = 34 
44.96 years, 61.73% female). Response rates demonstrated efficacy of high-frequency rTMS 35 
over the left DLPFC (OR = 3.75, 95% CI [2.44; 5.75]), right-sided low-frequency rTMS (OR 36 
= 7.44, 95%CI [2.06; 26.83]) bilateral rTMS (OR = 3.68,95%CI [1.66; 8.13]), deep TMS (OR 37 
= 1.69, 95%CI [1.003; 2.85]), intermittent TBS (OR = 4.70, 95%CI [1.14; 19.38]) and tDCS 38 
(OR = 4.17, 95% CI [2.25; 7.74]); but not for continuous TBS, bilateral TBS or synchronised 39 
TMS. There were no differences in all-cause discontinuation rates. The strongest evidence 40 
was for high-frequency rTMS over the left DLPFC. Intermittent TBS provides an advance in 41 
terms of reduced treatment duration. tDCS is a potential treatment for non-treatment resistant 42 
depression. To date, there is not sufficient published data available to draw firm conclusions 43 
about the efficacy and acceptability of TBS and sTMS. 44 
 45 
Keywords: transcranial magnetic stimulation, theta burst stimulation, transcranial direct 46 
current stimulation, depression, meta-analysis, brain stimulation, systematic review  47 
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Highlights 48 
• Response, remission, all-cause discontinuation rates and continuous post-treatment 49 
depression scores were examined 50 
• Several non-invasive brain stimulation treatments seem efficacious across different 51 
outcome metrics 52 
• All-cause discontinuation rates indicate no differences between sham and active 53 
treatment  54 
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Introduction 55 
Major depression is prevalent1 and associated with considerable disease burden2. Its course is 56 
often recurrent and may become chronic with relapse rates within one year of remission 57 
ranging from 35% to 80%3,4. The most common treatments are pharmacological and 58 
psychological therapies. Yet, even with a full course of treatment, at least one third of patients 59 
fail to achieve remission5. Non-invasive neurostimulation therapies, such as transcranial 60 
magnetic stimulation (TMS) and transcranial electrical stimulation (tES), offer a potential 61 
alternative or add-on treatment strategy. 62 
 63 
TMS was originally introduced as a tool for investigating and mapping cortical functions and 64 
connectivity6. TMS utilises intense, rapidly-changing electromagnetic fields generated by a 65 
coil of wire near the scalp and allows for a mostly undistorted induction of an electrical 66 
current to alter neural activity in relatively focal, superficial areas of the brain. Standard TMS 67 
involves single or paired pulses, while repetitive transcranial magnetic stimulation (rTMS) 68 
involves the delivery of repeated pulses which enable the prolonged modulation of neural 69 
activity. Depending on the stimulation frequency, rTMS can increase or decrease cortical 70 
excitability. The prevailing hypothesis is that the aftereffects of high-frequency (usually 10Hz 71 
or higher) stimulation are excitatory while those of low-frequency (≤1Hz) stimulation are 72 
inhibitory7. 73 
 74 
The rationale for using rTMS to treat depressive illness comes from clinical symptomatology 75 
and neuroanatomy as well as neuroimaging studies indicating functional impairments in 76 
prefrontal cortical and limbic regions8. In 2008, the US Food and Drug Administration (FDA) 77 
approved the first rTMS device for the treatment major depressive disorder (MDD) in which 78 
there was poor response to at least one pharmacological agent in the current episode9, and its 79 
clinical utilisation has increased since10. 80 
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 81 
As stimulation at high frequencies can be uncomfortable during the initial stimulation period, 82 
low-frequency rTMS may minimise the occurrence of undesired side effects, namely 83 
headaches and scalp discomfort, and may be associated with fewer adverse events, for 84 
instance by lowering the risk for developing seizures11. 85 
 86 
Bilateral applications of rTMS have also been developed: simultaneous stimulation over the 87 
left and right DLPFC (rDLPFC) or stimulation over one side followed by stimulation of the 88 
other side. These applications were hypothesised to be potentially additive or synergistic to 89 
reinstate any imbalance in prefrontal neural activity12. Moreover, there may be a selective 90 
unilateral response and the likelihood for a clinical response may increase by providing both 91 
types of stimulation13. 92 
 93 
Technical and methodological efforts to improve the antidepressant efficacy of TMS have led 94 
to several alternative treatment protocols. Deep TMS (dTMS) was FDA-approved in 2013, 95 
which is able to stimulate larger brain volumes and deeper structures14 that could be more 96 
directly relevant in the pathophysiology of depression (e.g., reward-mediating pathways and 97 
areas connected to the subgenual cingulate cortex)8,15,16. 98 
 99 
Another recent modification is theta burst stimulation (TBS)17, which is a patterned form of 100 
TMS pulse delivery that utilises high and low frequencies in the same stimulus train. TBS 101 
delivers bursts of three at a high frequency (50Hz) with an inter-burst interval of 5Hz in the 102 
theta range at 5Hz. Two different protocols are utilised: continuous theta burst stimulation 103 
(cTBS), which delivers 300 or 600 pulses without interruption, and intermittent theta burst 104 
stimulation (iTBS), which delivers 30 pulses every 10 seconds for a duration of 190 seconds, 105 
totalling 600 pulses18. It is suggested that cTBS reduces cortical excitability while iTBS 106 
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increases it, mimicking the processes of long-term potentiation and long-term depression, 107 
respectively17. Notably, there is some debate as to whether prolonged stimulation periods 108 
reverse the hypothesised effects of TBS19, while there is also support for a dose-response 109 
relationship for iTBS20. 110 
 111 
The main advantages of TBS are its reduced administration time, which is typically less than 112 
five minutes as opposed to 20–45 minutes for conventional rTMS, and the lower intensity 113 
needed to produce lasting neurophysiological effects as TBS is typically administered at 80% 114 
of the resting motor threshold (rMT) and might be more comfortable than stimulation at 115 
higher intensities typically used with standard rTMS. 116 
 117 
Synchronised TMS refers to magnetic low-field synchronised stimulation (sTMS), a new 118 
treatment paradigm that involves rotating spherical rare-earth (neodymium) magnets 119 
positioned sagittally along the midline of the scalp, which deliver stimulation synchronised to 120 
an individual’s alpha frequency21. The magnets are positioned to provide a global magnetic 121 
field distributed broadly across the midline cortical surface (one magnet over the frontal polar 122 
region, one magnet over the top of the head, and one magnet over the parietal region). The 123 
rationale for sTMS synchronised to an individual’s alpha frequency is the observation that 124 
one mechanism of action of rTMS is the entrainment of oscillatory activity to the 125 
programmed frequency of stimulation, thereby resetting thalamo-cortical oscillators and 126 
restoring normal endogenous oscillatory activity22. This modification of TMS may be 127 
associated with fewer treatment-emergent adverse and side effects because it does not cause 128 
neural depolarisation. It also uses less energy than conventional rTMS as it utilises sinusoidal 129 
instead of pulsed magnetic fields, which require less than 1% of the energy needed for 130 
conventional rTMS and may thus be less expensive. 131 
 132 
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Access and costs are among the major impediments to a more widespread use of rTMS, 133 
although costs may be lower for TBS and sTMS. A less expensive technique is transcranial 134 
electrical stimulation (tES). Its most commonly used protocol, transcranial direct current 135 
stimulation (tDCS), was reappraised as a tool in research through the work of Priori et al.23 136 
and Nitsche and Paulus24. tDCS involves the application of a low-amplitude electrical direct 137 
current through surface scalp electrodes to superficial areas of the brain. While it does not 138 
directly trigger action potentials, it modulates cortical excitability by shifting the neural 139 
membrane resting potential and these effects can outlast the electrical stimulation period25. 140 
The direction of such excitability changes may depend on the polarity of the stimulation: 141 
anodal stimulation is hypothesised to cause depolarisation and an increase in neural 142 
excitability, whereas cathodal stimulation causes hyperpolarisation and a decrease in cortical 143 
excitability26,27. 144 
 145 
The advantages of tDCS compared to TMS include its ease of administration, being much less 146 
expensive, its more benign side effect profile, and its portability which could potentially be 147 
used in the home environment28. 148 
 149 
We sought to perform a systematic review and meta-analysis of the antidepressant efficacy 150 
and acceptability of non-invasive neuromodulation in treating a current depressive episode in 151 
unipolar and bipolar depression from randomised sham-controlled trials. The only study to 152 
date that evaluated the efficacy of a range of rTMS techniques is Brunoni et al.'s network 153 
meta-analysis29. However, the analysis had included trials that had co-initiated other 154 
treatments (e.g. sleep deprivation and TMS); trials which had not included a sham treatment; 155 
had not separated the TBS modifications; and had not included any age-related exclusion 156 
criteria. Also, tDCS trials were not included in that meta-analysis. We sought to address these 157 
limitations by including only trials with randomised allocation to active or sham treatments, 158 
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excluding studies which had co-initiated another treatment, and limiting our sample to the 159 
adult age range as geriatric depression may impact on efficacy. 160 
 161 
Materials and Methods 162 
Search strategy and selection criteria 163 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 164 
(PRISMA) guidelines30. A systematic search of the Embase, Medline, and PsycINFO 165 
databases was performed from the first date available to 1st May 2018 (Figure 1). The 166 
following search terms were used: (bipolar disorder OR bipolar depression OR major 167 
depression OR unipolar depression OR unipolar disorder) AND (transcranial direct current 168 
stimulation OR tDCS OR transcranial magnetic stimulation OR TMS OR theta burst 169 
stimulation OR TBS OR sTMS OR dTMS), limiting searches to studies in humans and 170 
English-language publications. Reference lists of included papers and of recent systematic 171 
reviews and meta-analyses (Supplementary Material 1) were screened for further studies. This 172 
study has not been previously registered. 173 
 174 
Inclusion criteria were: 1) adults aged 18 – 70 years; 2) DSM or ICD diagnosis of MDD or 175 
bipolar disorder currently in a major depressive episode; 3) randomised sham-controlled 176 
trials, which utilised a parallel-group or cross-over design; 4) clinician-administered 177 
depression rating scale, Hamilton Depression Rating Scale (HDRS)31 or Montgomery-Åsberg 178 
Depression Rating Scale (MADRS)32. 179 
 180 
Exclusion criteria were: 1) primary diagnoses other than MDD or bipolar depression; 2) 181 
studies limited to a specific subtype of depression (e.g., postpartum depression or vascular 182 
depression) or in which a major depressive episode was a secondary diagnosis (e.g., 183 
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fibromyalgia and major depression); 3) co-initiation of any other form of treatment, such as 184 
pharmacotherapy or cognitive control training. 185 
 186 
Data analysis 187 
The following sample characteristics were extracted: sex, age, hospitalisation status, whether 188 
patients with psychotic symptoms were excluded from the study, diagnosis, treatment 189 
strategy, and treatment resistance. 190 
 191 
The following treatment-related parameters were extracted. For TMS: type of coil and sham 192 
procedure, coil location, stimulation frequency (Hz) for each site, stimulation intensity 193 
(percentage of the rMT), total number of pulses delivered, and number of treatment sessions. 194 
For TBS: data on the treatment protocol (iTBS, cTBS or bilateral TBS) were also recorded. 195 
For tDCS: location of the anode and cathode, electrode size (cm2), current intensity (mA) and 196 
density (mA/cm2), session duration, number of sessions, and duration of active stimulation in 197 
the sham condition. 198 
 199 
The primary outcome measure was clinical response, defined as a ≥ 50% reduction in 200 
symptom scores at the primary study endpoint. Remission rates were the secondary outcome 201 
measure based on the definition provided by each study. If response or remission rates were 202 
reported for both HDRS and MADRS, data for the HDRS were selected to facilitate 203 
comparability between trials. If data for multiple versions of the HDRS were reported, the 204 
original 17-item version was selected. We also extracted baseline and post-treatment 205 
depression severity scores; the latter constituted our tertiary outcome measure. If available, 206 
the intention-to-treat (ITT) or modified intention-to-treat (mITT) data were preferred over 207 
data based only on completers. For cross-over trials, only data from the initial randomisation 208 
were used to avoid carry-over effects. Data presented in figures were extracted with 209 
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WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/app/). All-cause discontinuation rates 210 
were recorded separately for active and sham groups and were treated as a primary outcome 211 
measure of acceptability. 212 
 213 
Data that could not be directly retrieved from the original publications were requested from 214 
the authors or searched for in previous systematic reviews and meta-analyses. For trials with 215 
more than two groups that could not be included as separate treatment comparisons, we 216 
combined groups to create single pair-wise comparisons. 217 
 218 
For dichotomous outcome data, odds ratios (Mantel-Haenszel method) were used as an index 219 
of effect size. We also computed Hedge’s g to estimate the effect sizes for continuous post-220 
treatment depression scores. A random-effects model was chosen as it was assumed that the 221 
underlying true effect size would vary between studies. A random-effects model provides 222 
wider confidence intervals than a fixed-effects model if there is significant heterogeneity 223 
among studies and thus tends to be more conservative in estimating summary effect sizes. 224 
 225 
Contour-enhanced funnel plots33 were visually inspected to assess whether potential funnel 226 
asymmetry is likely to be due to statistical significance-based publication bias. 227 
 228 
Heterogeneity between studies was assessed with the QT statistic, which estimates whether the 229 
variance of effect sizes is greater than what would be expected due to sampling error. A p 230 
value smaller than .01 provides an indication for significant heterogeneity34. The I2 statistic 231 
was computed for each analysis to provide a descriptive measure of inconsistency across the 232 
results of individual trials included in our analyses. It provides an indication of what 233 
percentage of the observed variance in effect sizes reflects real differences in effect sizes as 234 
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opposed to sampling error. Higgins et al.35 suggested that 25%, 50%, and 75% represent little, 235 
moderate, and high heterogeneity, respectively. 236 
 237 
Where sufficient data were available, we conducted subgroup analyses to examine potential 238 
differences in antidepressant efficacy by clinical and study characteristics including diagnosis, 239 
whether the trial excluded patients with psychotic symptoms, hospitalization status and 240 
treatment resistance. 241 
 242 
Analyses were conducted using the ‘meta’ package36 for RStudio (Version 0.98.932) and 243 
STATA (Version 13.1; StataCorp, 2013) was used for data processing. 244 
 245 
The Cochrane tool for assessing risk of bias in randomised trials37 was used to evaluate 246 
included studies. Each trial received a score of low, high, or unclear risk of bias for each of 247 
the potential sources of bias. Two raters independently conducted the assessment of risk of 248 
bias. 249 
 250 
Results 251 
Overview 252 
Fifty-six RCTs, consisting of 131 treatment arms met our criteria for inclusion (Figure 1, 253 
Supplementary Material 2). Overall, 66 treatment comparisons were included, total N = 3,058 254 
patients (mean age = 44.96 years, 61.73% female) of whom n = 1,598 were randomised to 255 
active and n = 1,460 to sham treatments (Tables 1-4). 256 
 257 
Visual inspection of the contour-enhanced funnel plots did not suggest small study effects 258 
(Figure 2; Supplementary Material 3). However, due to the small number of studies for 259 
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treatment modalities other than left-sided high-frequency rTMS and tDCS, these need to be 260 
interpreted with caution. The results of our risk of bias assessment are presented in 261 
Supplementary Material 4. 262 
 263 
Response and remission rates 264 
Sixty-two comparisons of experimental and sham treatment arms met the inclusion criteria for 265 
the meta-analysis of response rates (Table 5; Figure 3), and 50 treatment comparisons for the 266 
meta-analysis of remission rates (Table 6; Figure 4). 267 
 268 
High-frequency rTMS over the left DLPFC (lDLPFC) was associated with improved rates of 269 
response as well as remission in comparison with sham treatment. The odds ratio of response 270 
was OR = 3.75 compared to sham (k = 32, 95% CI [2.44; 5.75]). There was little evidence 271 
that the heterogeneity between trials exceeded that expected by chance (I2 = 26.1%; Q31= 272 
41.96, p = .09). Sensitivity analyses suggested similar effect sizes in trials that had recruited 273 
patients with unipolar depression only and those that had recruited both patients with unipolar 274 
and bipolar depression (Supplementary Figure 3a).Only one pilot study38 had recruited 275 
patients with bipolar depression only, but provided no support for antidepressant efficacy (OR 276 
= 1.14, 95% CI [0.21; 6.37]). Response rates were greater in trials that (i) excluded patients 277 
with psychotic features, (ii) recruited outpatients only, and (iii) recruited either treatment 278 
resistant patients only or both treatment resistant patients and those that were not treatment 279 
resistant (Supplementary Figures 3b-3d). 280 
 281 
The odds of achieving remission were over twice that of sham (k = 26, OR = 2.51, 95% CI 282 
[1.62; 3.89]). There was no evidence for significant heterogeneity (I2 = 1.4%; Q25 = 22.35, p = 283 
.44). Sensitivity analyses for remission rates were in line with those for response rates, 284 
although we did not find left-sided high-frequency rTMS to be effective in samples that had 285 
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recruited both treatment resistant and non-treatment resistant patients (Supplementary Figures 286 
6a-6d). 287 
 288 
Low-frequency rTMS over the rDLPFC was also associated with significantly greater 289 
response and remission rates than sham stimulation. There was a sevenfold improvement in 290 
response rates compared to sham (k = 3, OR= 7.44 (95% CI [2.06; 26.83]), with no indication 291 
for significant heterogeneity between trials (I2 = 0.0%; Q2= 1.59, p = .45). No sensitivity 292 
analyses were conducted due to the small number of treatment comparisons. 293 
 294 
The odds of remission were greater than those of sham (k = 2, OR = 14.10 (95% CI [2.79; 295 
71.42]). Heterogeneity between trials was not greater than expected due to sampling error (I2 296 
= 0.0%; Q1 = 0.50, p = .48). No sensitivity analyses were conducted due to the small number 297 
of treatment comparisons. 298 
 299 
Low-frequency rTMS over the lDLPFC was not associated with any significant 300 
improvements in rates of response or remission. There were no significant differences in 301 
response rates compared to sham (k = 3, OR = 1.41, 95% CI [0.15; 12.88]). The heterogeneity 302 
between trials did not exceed that expected by chance (I2 = 0.0%; Q2 = 0.14, p = .93), and no 303 
sensitivity analyses were conducted due to the small number of treatment comparisons. There 304 
were no significant differences in remission rates compared to sham (k = 3, OR = 0.86, 95% 305 
CI [0.08; 9.11]). The variance in effect sizes between trials was no greater than expected due 306 
to sampling error (I2 = 0.0%; Q2 = 0.03, p = .98). No sensitivity analyses were conducted due 307 
to the small number of treatment comparisons. 308 
 309 
Bilateral rTMS was associated with significant improvement in response but not remission 310 
rates compared to sham. There was a significant improvement in response rates compared to 311 
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sham (k = 6, OR = 3.68 (95% CI [1.66; 8.13]), and the variance in effect sizes between trials 312 
did not exceed that expected due to sampling error (I2 = 0.0%; Q5 = 3.45, p = .63). Sensitivity 313 
analyses suggested subgroup differences according to whether trials had excluded psychotic 314 
patients or had recruited patients with diagnosis of MDD only, bipolar depression only, or 315 
both MDD and bipolar depression (Supplementary Figures 4a,4b).We found no evidence for a 316 
significant improvement in rates of remission associated with bilateral TMS compared to 317 
sham (k = 5, OR = 3.05, 95% CI [0.87; 10.67]). There was no evidence for significant 318 
heterogeneity between trials (I2 = 10.7%; Q4 = 4.48, p = .34), and sensitivity analyses 319 
suggested no differences according to any patient characteristics tested (Supplementary 320 
Figures 7a,7b). 321 
 322 
There were significant improvements in both response and remission rates for dTMS 323 
compared to sham. The response rates were marginally higher while statistically significant 324 
for dTMS relative to sham (k =2, OR = 1.69, 95% CI [1.003; 2.85]). The variance in effect 325 
sizes between trials did not exceed that expected due to sampling error (I2 = 0.0%; Q1 = 0.97, 326 
p = .33). No sensitivity analyses were conducted due to the small number of treatment 327 
comparisons. The remission rates were greater for dTMS compared to sham (k = 2, OR = 328 
2.24, 95% CI [1.24; 4.06]). There was no evidence for significant heterogeneity between trials 329 
(I2 = 0.0%; Q1 = 0.02, p = 0.88), and no sensitivity analyses were conducted due to the small 330 
number of treatment comparisons. 331 
 332 
Neither response nor remission rates for sTMS were significantly higher than for sham. There 333 
was no evidence for increased response rates compared to sham (k = 2, OR = 2.71, 95% CI 334 
[0.44; 16.86]). There was significant heterogeneity between these two studies (I2 = 75.9%; 335 
Q1= 4.15, p = .04). No sensitivity analyses were conducted due to the small number of 336 
treatment comparisons. There were also no significant improvements in remission rates for 337 
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sTMS compared to sham (k= 2, OR = 2.51 (95% CI [0.23; 26.76]). There was evidence for 338 
significant heterogeneity between the two studies though (I2 = 75.7%; Q1 = 4.12, p = .04). No 339 
sensitivity analyses were conducted due to the small number of treatment comparisons. 340 
 341 
iTBS over the lDLPFC was associated with a fivefold improvement in response rates 342 
compared to sham (k = 2, OR = 4.70 (95% CI [1.14; 19.38]). The heterogeneity between trials 343 
did not exceed that expected by chance (I2 = 0.0%; Q1 = 0.02, p = .89). No sensitivity 344 
analyses were conducted due to the small number of treatment comparisons. For only one 345 
trial39 was data on remission rates for iTBS available, with no evidence for antidepressant 346 
efficacy compared to sham. 347 
 348 
Neither cTBS over the rDLPFC nor bilateral TBS were statistically different from sham in 349 
terms of response rates (k = 1, OR = 1.63, 95% CI [0.23; 11.46] and k = 2, OR = 4.28, 95% CI 350 
[0.54; 34.27]). For bilateral TBS there was evidence that the variance in effect sizes between 351 
studies was greater than what would be expected due to sampling error (I2 = 65.7%; Q1 = 352 
2.91, p = .09). No sensitivity analyses were conducted due to the small number of treatment 353 
comparisons. The only trial of bilateral TBS for which remission rates were available40 found 354 
no evidence for its antidepressant efficacy compared to sham. No remission rates were 355 
available for cTBS. 356 
 357 
tDCS was associated with significant improvement in both response and remission rates in 358 
comparison to sham stimulation. There was a significant improvement in response rates 359 
relative to sham (k = 9, OR = 4.17, 95% CI [2.25; 7.74]). There was little evidence for 360 
significant heterogeneity between studies (I2 = 26.2%; Q8 = 10.83, p = .21) and sensitivity 361 
analyses suggested tDCS to be effective only in patients with non-treatment resistant 362 
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depression and in trials that had recruited patients with both treatment resistant and non-363 
treatment resistant depression (Supplementary Figure 5). 364 
 365 
The analysis of remission rates showed a statistically significant advantage of tDCS compared 366 
to sham (k = 8, OR = 2.88, 95% CI [1.65; 5.04]). There was no indication for significant 367 
heterogeneity between trials (I2 = 0.0%; Q7 = 6.32, p = .50), and sensitivity analyses found 368 
that only trials that had recruited patients with both treatment resistant and non-treatment 369 
resistant depression provided evidence for antidepressant efficacy (Supplementary Figure 8). 370 
 371 
Effects on continuous measures 372 
Forty-six treatment comparisons reported post-intervention continuous depression scores. 373 
There was evidence for the antidepressant efficacy of high-frequency rTMS over the lDLPFC 374 
compared to sham (k = 29, Hedge’s g = -0.72, 95% CI [-0.99; -0.46]), dTMS compared to 375 
sham (k = 2, Hedge’s g = -0.29, 95% CI [-0.55; -0.03]), and tDCS compared to sham (k = 7, 376 
Hedge’s g = -0.76, 95% CI [-1.31; -0.21]). There was evidence for significant heterogeneity 377 
between trials for several treatment modalities (Table 7; Figure 5). 378 
 379 
Acceptability 380 
Sixty-four treatment comparisons were available for all-cause discontinuation rates. There 381 
were no significant differences in drop-out rates for any treatment modalities (Table 8; Figure 382 
6). 383 
 384 
Discussion 385 
The present systematic review and meta-analysis examined the efficacy and acceptability of 386 
non-invasive brain stimulation techniques for a current depressive episode in unipolar and 387 
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bipolar depression. We sought to investigate the efficacy of the brain stimulation techniques 388 
without the potential confound of co-initiation of another treatment and in trials which had 389 
included randomised allocation to a sham stimulation treatment arm in order to account for 390 
potential placebo effects. 391 
 392 
The largest evidence base to date is for high-frequency rTMS over the lDLPFC which is 393 
associated with 3.75 times greater odds of response than sham stimulation as well as odds of 394 
remission that are 2.52 times greater than sham. These findings are consistent with previous 395 
systematic reviews and meta-analyses41 and have led to the consensus review and treatment 396 
guideline by the Clinical TMS Society for daily high-frequency rTMS over the lDLPFC for 397 
the treatment of medication-resistant or medication-intolerant depressive episodes42. 398 
 399 
Additional support for treatment efficacy was revealed for low-frequency rTMS over the 400 
rDLPFC, which was associated with improved rates of response as well as remission. 401 
Bilateral rTMS was associated with higher rates of response but not remission. It is unclear 402 
whether any advantages of bilateral rTMS compared to left-sided high-frequency or right-403 
sided low-frequency rTMS would be due to the treatment protocol. As bilateral stimulation 404 
delivers a greater number of pulses than unilateral stimulation, unless the number of treatment 405 
sessions or the treatment duration are adjusted for accordingly, it is difficult to reliably assess 406 
whether the difference in stimulation protocol (bilateral vs. unilateral stimulation) or the 407 
difference in the number of stimuli delivered leads to differences in clinical effects43. 408 
 409 
To date, no studies have directly compared dTMS and standard rTMS protocols. In an 410 
exploratory meta-analysis of nine open-label trials, including a total of 150 patients, Kedzior 411 
et al.44 provided evidence for the antidepressant efficacy of dTMS. The present meta-analysis 412 
found that dTMS was associated with 1.69 times greater odds of response and 2.24 greater 413 
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odds of remission than sham which were statistically significant. While the open-label trials 414 
included in Kedzior et al.'s analysis may have overestimated the true efficacy of dTMS, we 415 
provide initial support for the clinical efficacy of dTMS that was greater than for sham 416 
treatment but less than for high-frequency rTMS over the lDLPFC, low-frequency rTMS over 417 
the rDLPFC or bilateral rTMS. 418 
 419 
The meta-analytic estimates did not indicate significant treatment effects associated with low-420 
frequency rTMS over the lDLPFC or with sTMS. However, these have been trialled in 421 
onlythree45-47 and twostudies21,48, respectively. Specific treatment effects of TMS that depend 422 
on side and frequency of stimulation have been proposed but it may be possible that low-423 
frequency rTMS over the lDLPFC has a marginal effect in at least a small number of 424 
patients47. Leuchter et al.48 found sTMS to only be effective when administered at the 425 
individual’s alpha frequency and with a minimum of 80% treatment adherence, suggesting a 426 
dose-response relationship. 427 
 428 
With theta burst stimulation, the duration of each treatment session is reduced to a few 429 
minutes. Our meta-analysis did demonstrate almost five times greater odds of response 430 
compared to sham for iTBS over the lDLPFC. However, this estimate is based on two trials 431 
only. One trial had examined remission rates as well39, reporting remission rates of 0% for 432 
sham and 9.1% for active stimulation. The meta-analytic estimates for cTBS and the bilateral 433 
modification of TBS did not show any advantage over sham in terms of response rates. The 434 
only trial that reported remission rates for bilateral TBS did not provide evidence for its 435 
antidepressant efficacy either and no data were available to evaluate remission rates following 436 
cTBS. 437 
 438 
Transcranial direct current stimulation is a form of neurostimulation that offers greater 439 
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portability and lower costs relative to TMS. The meta-analysis revealed significant 440 
improvements in response and remission rates following tDCS treatment in comparison to 441 
sham, which was 4.17 times greater for response rates and 2.88 times greater for remission 442 
rates. We have been able to identify the effects of tDCS without potential confounds of co-443 
initiation of another treatment, revealing significantly greater odds of response as well as 444 
remission49. The clinical efficacy of tDCS is evident also in the non-treatment resistant form 445 
of depression, in contrast to most rTMS trials, suggesting that tDCS is a potential initial 446 
therapeutic option for depression. 447 
 448 
The finding that there were no differences in terms of drop-out rates at study end between the 449 
active treatment and sham conditions for any treatment modality suggests that non-invasive 450 
brain stimulation is generally well tolerated by patients. We chose all-cause discontinuation 451 
rates based on the intention-to-treat sample, representing the most conservative estimate of 452 
treatment acceptability. 453 
 454 
We chose response and remission rates as our main outcome measures, which are commonly 455 
used in the medical sciences and arguably constitute clinically-useful estimates of the 456 
antidepressant efficacy of treatment. However, the dichotomisation of outcome data has 457 
received criticism because it is known to produce a loss of signal and might inflate Type I 458 
error rates, for example an individual who has a 49% reduction in their depressive severity 459 
scores would not be included in the clinical response rate while a 51% reduction would be 460 
included in the response rate50. To address these limitations, we had also analysed continuous 461 
depression severity scores. However, outcome data were not reported for each trial, and some 462 
missing data could not be obtained. Studies have also suggested that the antidepressant 463 
efficacy of active stimulation may separate from sham only after multiple weeks of treatment, 464 
for both rTMS9 and cTBS51. We had examined the acute antidepressant effects at primary 465 
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study endpoint, and we cannot estimate the long-term effects. 466 
 467 
A significant number of TMS studies used active magnetic stimulation with the coil being 468 
angulated at 45 or 90 degrees to the scalp surface as sham condition. Because differences in 469 
coil orientation may produce considerably different sensations on the scalp and coil 470 
angulation might still produce a limited degree of intracortical activity52, ensuring a valid 471 
control condition constitutes a methodological challenge. One study placed an inactive coil on 472 
the patient’s head while discharging an active coil at least one meter away in order to mimic 473 
the auditory effects of rTMS53. 474 
 475 
A more recent approach is to use a specifically designed sham coil that does not generate a 476 
magnetic field but is visually and auditorily indistinguishable from an active coil. A meta-477 
analysis by Berlim et al.54 found no significant differences between the number of patients 478 
who correctly guessed their treatment allocation when comparing active high-frequency left-479 
sided or bilateral rTMS and sham. There were also no significant differences between studies 480 
that utilised angulated coils and sham coils. Blinding integrity is less of a methodological 481 
hurdle for sTMS trials because neither active stimulation nor sham procedure produce any 482 
physical sensation, they look identical, and are comparable in terms of acoustic artefacts. 483 
Only few of the more recent modifications of TMS reported on the adequacy of their blinding 484 
procedure. Given that cross-over designs are particularly prone to unblinding after cross-over, 485 
we included only data corresponding to the initial randomisation in our analyses. 486 
 487 
For tDCS, the sham condition typically involves delivering active stimulation for up to 30 488 
seconds, which mimics the initial somatic sensations without inducing a therapeutic effect. 489 
However, the adequacy of blinding of tDCS sham has also been called into question55. 490 
 491 
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The clinical trials had enrolled patients based on a diagnostic assessment of clinical symptoms 492 
rather than underlying brain pathology. The potential for biological heterogeneity might mask 493 
the clinical efficacy of non-invasive brain stimulation in some trials but could not be assessed 494 
in the present analysis. We implemented reasonably strict inclusion criteria to limit the 495 
influence of a range of potential confounders, for example we excluded RCTs that co-initiated 496 
treatment with medication. However, potential effects of specific medications on the clinical 497 
efficacy of brain stimulation could not be adequately controlled for as patients often had a 498 
large number of heterogeneous treatments prior to enrolling, which might have distorted the 499 
clinical effects of brain stimulation. 500 
 501 
Finally, compared to the network meta-analysis (NMA) on TMS29, we were not able to 502 
compare the active treatments. In the NMA priming rTMS seemed most effective. However, 503 
the two RCTs that used this treatment modality compared it with another active stimulation 504 
and could not be included in the present meta-analysis. 505 
 506 
Conclusion 507 
The present systematic review and meta-analysis supports the efficacy and acceptability of 508 
non-invasive brain stimulation techniques in adult unipolar and bipolar depression. The 509 
strongest evidence was for high-frequency rTMS over the lDLPFC, followed by low-510 
frequency rTMS over the rDLPFC and bilateral rTMS. Intermittent TBS provides a potential 511 
advance in terms of reduced treatment duration and the meta-analysis did find support for 512 
improved rates of response. tDCS is a potential treatment for non-resistant depression which 513 
has demonstrated efficacy in terms of response as well as remission. All the trials included in 514 
the present meta-analysis had included randomised allocation to a sham treatment arm and we 515 
had excluded trials in which there was co-initiation of another treatment. Some of the more 516 
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recent treatment modalities though require additional trials and more direct comparisons 517 
between different treatment modalities are warranted. 518 
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Figure 1 545 
Caption: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 546 
flow diagram of literature search. 547 
 548 
Figure 2 549 
Caption: Contour-enhanced funnel plot of all RCTs included in the meta-analysis of response 550 
rates. 551 
Legend: rTMS (black); tDCS (navy); TBS (red); dTMS (yellow): sTMS (pink). 552 
 553 
Figure 3 554 
Caption: Forest plot of response rates. 555 
 556 
Figure 4 557 
Caption: Forest plot of remission rates. 558 
 559 
Figure 5 560 
Caption: Forest plot of post-treatment continuous depression scores. 561 
 562 
Figure 6 563 
Caption: Forest plot of all-cause discontinuation rates.  564 
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Table 1 
Treatment characteristics: TMS studies 
Authors Location Frequency (Hz) % rMT 
Total 
pulses 
Sessions 
Treatment 
strategy 
Active group Sham group 
HF-L  Left Right       
Anderson et al., 2007 LDLPFC 10 - 110a 12,000 12 Mixed Figure-of-eight Sham-coil 
Avery et al., 2006 LDLPFC 10 - 110b 24,000 15 Mixed Figure-of-eight 90° 
Avery et al., 1999 LDLPFC 10 - 80 NR 10 Mixed NR 45° 
Baeken et al., 2013* LDLPFC 20 - 110 31,200 20 Monotherapy Figure-of-eight 90° 
Bakim et al., 20121 LDLPFC 20 - 80; 100 24,000 30 Augmentation Figure-of-eight 45° 
Berman et al., 2000 LDLPFC 20 - 80 NR 10 Monotherapy Figure-of-eight 30-45° 
Bortolomasi et al., 2007 LDLPFC 20 - 90 4,000 5 Mixed Circular 90° 
Boutros et al., 2002 LDLPFC 20 - 80 8,000 10 Mixed Figure-of-eight 90° 
Chen et al., 2013 LDLPFC 20 - 90 NR 10 Augmentation Figure-of-eight 90° 
Concerto et al., 2015 LDLPFC 10 - 120 60,000 20 Augmentation Figure-of-eight 45° 
Eschweiler et al., 2000* LDLPFC 10 - 90 NR 5 Augmentation Figure-of-eight 90° 
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Fitzgerald et al., 2012 (1) LDLPFC 10 - 120 NR 15 Mixed Figure-of-eight 45° 
Fitzgerald et al., 2003 (1) LDLPFC 10 - 100 10,000 10 Augmentation Figure-of-eight 45° 
Garcia-Toro et al., 2001 LDLPFC 20 - 90 NR 10 Augmentation Figure-of-eight 90° 
George et al., 2010 LDLPFC 10 - 120 45,000 15 Monotherapy Figure-of-eight Sham-coil 
George et al., 20002 LDLPFC 5; 20c - 100d 16,000 10 Monotherapy Figure-of-eight 45° 
George et al., 1997* LDLPFC 20 - 80 8000 10 Mixed Figure-of-eight 45° 
Hansen et al., 2004 LDLPFC 10 - 90 30,000 15 Augmentation Figure-of-eight 90° 
Hernández-Ribas et al., 2013 LDLPFC 15 - 100 22,500 15 Augmentation Figure-of-eight 90° 
Holtzheimer et al., 2004 LDLPFC 10 - 110 16,000 10 Monotherapy Figure-of-eight 45°e 
Jakob et al., 2008 (1) LDLPFC 20 - 100 20,000 10 Mixed Figure-of-eight Sham-coil 
Jakob et al., 2008 (2) LDLPFC 50 - 100 20,000 10 Mixed Figure-of-eight Sham-coil 
Kimbrell et al., 1999* LDLPFC 20 - 80 8,000 10 Monotherapy Figure-of-eight 45° 
Kreuzer et al., 2015 LDLPFC 10 - 110 30,000 15 Augmentation Figure-of-eight Sham-coil 
Lingeswaran et al., 2011 LDLPFC 10 - 100 NR 12 NR Figure-of-eight 90° 
Loo et al., 1999* LDLPFC 10 - 110 NR 10 Mixed Figure-of-eight 90° 
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Nahas et al., 2003 LDLPFC 5 - 110 16,000 10 Monotherapy Figure-of-eight 45° 
O'Reardon et al., 2007 LDLPFC 10 - 120g 60,000 20 Monotherapy Figure-of-eight Sham-coil 
Paillère-Martinot et al., 2010 LDLPFC 10 - 90 16,000 10 Augmentation Figure-of-eight Sham-coil 
Speer et al., 2014 LDLPFC 20 - 110 24,000 15 Monotherapy Figure-of-eight 45° 
Su et al., 20053 LDLPFC 5; 20 - 100 16,000 10 Augmentation Figure-of-eight 90° 
Taylor et al., 2018 LDLPFC 10 - 120g 60,000 20 Mixed Figure-of-eight Sham-coil 
Theleritis et al., 2017 (1) LDLPFC 20 - 100 24,000 15 Mixed Figure-of-eight 90° 
Theleritis et al., 2017 (2) LDLPFC 20 - 100 48,000 30f Mixed Figure-of-eight 90° 
Zheng et al., 2010 LDLPFC 15 - 110g 60,000 20 Augmentation Figure-of-eight 90° 
LF-R          
Fitzgerald et al., 2003 (2) RDLPFC - 1 100 3,000 10 Augmentation Figure-of-eight 45° 
Januel et al., 2006 RDLPFC - 1 90 1,920 16 Monotherapy Figure-of-eight Sham-coil 
Pallanti et al., 2010 (1) RDLPFC - 1 110 6,300 15 Augmentation Figure-of-eight Sham-coil 
LF-L 
Kimbrell et al., 1999* LDLPFC 1 - 80 8,000 10 Monotherapy Figure-of-eight 45° 
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Padberg et al., 1999 LDLPFC 0.3 - 90 1,250 5 Mixed Figure-of-eight 90° 
Speer et al., 2014 LDLPFC 1 - 110 24,000 15 Monotherapy Figure-of-eight 45° 
BL          
Fitzgerald et al., 2006 DLPFC 10 1 110(R); 100(L) 7,200 10 Mixed Figure-of-eight 45° 
Fitzgerald et al., 2016 DLPFC 10 1 110 40,000 20 Mixed Figure-of-eight 45° 
Fitzgerald et al., 2012 (2) DLPFC 10 1 120 NR 15 Mixed Figure-of-eight 45° 
McDonald et al., 20064 DLPFC 10 1 110 16,000 10 Monotherapy Figure-of-eight 90° 
Pallanti et al., 2010 (2) DLPFC 10 1 110(R); 100(L) 21,300 15 Augmentation Figure-of-eight Sham-coil 
Prasser et al., 2015 (1) DLPFC 10 1 110 30,000 15 Augmentation Figure-of-eight Sham-coil 
iTBS          
Duprat et al., 2016* LDLPFC 50 - 110 32,400 20i Monotherapy Figure-of-eight Sham-coil 
Li et al., 2014 (1) LDLPFC 50 - 80j 18,000 10 Mixed Figure-of-eight 90° 
cTBS          
Li et al., 2014 (2) RDLPFC 50 - 80j 18,000 10 Mixed Figure-of-eight 90° 
BLTBS          
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Li et al., 2014 (3) DLPFC 50 50 80j 36,000 10 Mixed Figure-of-eight 90° 
Prasser et al., 2015 (2) DLPFC 50 50 80 36,000 15 Augmentation Figure-of-eight Sham-coil 
dTMS          
Levkovitz et al., 2015 LDLPFC 18 - 120h 39,600 20 Monotherapy H1 Sham-coil 
Tavares et al., 2017 LDLPFC 18 - 120 39,600 20 Augmentation H1 Sham-coil 
sTMS          
Jin et al., 20145 Midline IAF; 8-13 - - 20 Augmentation sTMS NMRS 
Leuchter et al., 2015 Midline IAF - - 30 Monotherapy sTMS NMRS 
Note. Numbers in parentheses behind authors indicate that multiple active treatment arms of the same study are reported. Hz = hertz; rMT = resting motor threshold; LDLPFC = 
left dorsolateral prefrontal cortex; RDLPFC = right dorsolateral prefrontal cortex; TMS = transcranial magnetic stimulation; HF-L = high-frequency, left-sided repetitive 
transcranial magnetic stimulation; LF-R = low-frequency, right-sided repetitive transcranial magnetic stimulation; BL = bilateral repetitive transcranial magnetic stimulation; 
iTBS = intermittent theta burst stimulation; cTBS = continuous theta burst stimulation; BLTBS = bilateral theta burst stimulation; dTMS = deep transcranial magnetic 
stimulation; sTMS = synchronised transcranial magnetic stimulation; IAF = individual alpha frequency; NMRS = non-magnetic rotating shaft; NR = not reported. *Cross-over 
design. 1-5Two active treatment groups were combined. aTwo patients received active stimulation at 100% rMT. bStimulation delivered at estimated prefrontal threshold. cDuring 
the 5th session, stimulation was delivered for 2min at 10Hz. dDuring the 5th session, stimulation was delivered for 2min at 60% rMT. eTwo patients received sham treatment with 
the coil angulated at 90°. fReceived treatment twice daily. gDuring the first week, 110% rMT could be used for tolerability. hDuring the first three treatment session, rMT could be 
titrated from 100% to 120%. iReceived treatment five times daily. jStimulation delivered at active motor threshold.  
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Table 2 
Sample characteristics: TMS studies 
Authors 
Number of 
participants (female) 
Age Diagnosis HDRS / MADRS 
Excluded 
psychosis 
Status 
Treatment 
resistance 
 Active Sham Active Sham  Active Sham    
HF-L 
Anderson et al., 20071 13 (7) 16 (9) 48.0 (8.0) 46.0 (12.0) MDD 
26.7 (3.6)M 27.7 (7.1)M 
No Outpatient Mixed 
Avery et al., 20062 35 (21) 33 (16) 44.3 (10.3) 44.2 (9.7) MDD 23.5 (3.9)a 23.5 (2.9)a Yes NR TRD 
Avery et al., 1999 4 (4) 2 (1) 44.3 (10.1) 45.0 (7.1) Mixed 21.3 (6.7)b 19.5 (8.1)b Yes Outpatient TRD 
Baeken et al., 2013 9 (7) 11 (5) 51.8 (12.1) 47.3 (13.7) MDD 24.8 (7.1)a 26.5 (8.7)a Yes Mixed TRD 
Bakim et al., 20123 23 (20) 12 (11) 40.8 (10.0) 44.4 (10.2) MDD 23.6 (3.6)a 25.6 (3.8)a Yes Outpatient TRD 
Berman et al., 20002 10 (2) 10 (4) 45.2 (9.5) 39.4 (10.8) Mixed 37.1 (9.7)c 37.3 (8.5)c No Mixed TRD 
Bortolomasi et al., 2007 12 (7) 7 (4) NR NR Mixed 25.17 (7.84)d 21.57 (2.15)d No Inpatient TRD 
Boutros et al., 20026 12 (4) 9 (1) 49.5 (8.0) 52.0 (7.0) MDD 34.4 (10.1)c 31.7 (4.9)c No Outpatient TRD 
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Chen et al., 2013 10 (7) 10 (4) 44.1 (4.4) 47.3 (3.5) MDD 23.5 (1.9)a 24.9 (1.9)a No Inpatient TRD 
Concerto et al., 2015 15 (6) 15 (7) 51.0 (6.5) 53.0 (6.7) MDD 22.0 (21.0; 24.0)b 21.0 (20.0; 22.0)b Yes Outpatient TRD 
Eschweiler et al., 2000 5 (NR) 5 (NR) NR NR MDD 27.4 (4.6)b 20.2 (3.8)b No NR non-TRD 
Fitzgerald et al., 2012 (1)2 24 (15) 20 (8) 43.4 (12.7) 44.9 (15.7) MDD 23.7 (3.8)a 22.8 (2.1)a No NR TRD 
Fitzgerald et al., 2003 (1) 20 (8) 20 (11) 42.2 (9.8) 49.2 (14.2) Mixed 36.1 (7.5)M 35.7 (8.1)M No Outpatient TRD 
Garcia-Toro et al., 2001 17 (7) 18 (8) 51.5 (15.9) 50.0 (11.0) MDD 27.1 (6.7)b 25.6 (4.9)b No NR TRD 
George et al., 20102 92 (58) 98 (50) 47.7 (10.6) 46.5 (12.3) MDD 26.3 (5.0)d 26.5 (4.8)d Yes Outpatient TRD 
George et al., 20004 20 (13) 10 (6) 42.4 (10.5) 48.5 (8.0) Mixed 28.2 (5.9)b 23.8 (4.1)b Yes Outpatient Mixed 
George et al., 1997 7 (6) 5 (5) 42.4 (15.5) 41.0 (8.3) Mixed 30.0 (4.0)b 26.0 (3.0)b Yes Outpatient non-TRD 
Hansen et al., 20046 6 (2) 7 (2) 42.5 (38; 58)13 46 (44; 62)13 Mixed 26.5 (21.5; 27.6)a 23.8 (19.4; 28.0)a No Inpatient NR 
Hernández-Ribas et al., 2013 10 (8) 11 (8) 42.6 (5.6) 50.1 (8.1) Mixed 19.7 (3.8)b 16.6 (2.4)b Yes Outpatient TRD 
Holtzheimer et al., 2004 7 (4) 8 (3) 40.4 (8.5) 45.4 (4.9) MDD 22.7 (5.3)a 20.8 (6.3)a Yes Outpatient TRD 
Jakob 2008 (1) 12 (6) 12 (5) NR NR MDD 27.2 (NR)a 23.9 (NR)a NR NR NR 
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Jakob 2008 (2) 12 (7) 12 (5) NR NR MDD 24.1 (NR)a 23.9 (NR)a NR NR NR 
Kimbrell et al., 1999 5 (2) 3 (1) 40.2 (15.1) 43.7 (19.1) Mixed 25.0 (6.6)b 24.3 (6.8)b No Mixed TRD 
Kreuzer et al., 2015 15 (8) 12 (8) 46.1 (9.5) 43.8 (10.5) Mixed 22.3 (4.7)b 22.3 (4.7)b No Inpatient NR 
Lingeswaran et al., 2011 9 (6) 14 (8) 34 (10.5) 37.2 (11.8) MDD 22.8 (3.7)a 22.0 (3.1)a Yes Mixed NR 
Loo et al., 1999 9 (NR) 9 (NR) 45.7 (14.7) 50.9 (14.7) Mixed 21.5 (NR)a 25.1 (NR)a No Mixed TRD 
Nahas et al., 2003 11 (7) 12 (7) 42.4 (7.3) 43.4 (9.3)11 BD12 32.5 (4.3)e 32.8 (7.6)e NA Outpatient NR 
O'Reardon et al., 20076 155 (86) 146 (74) 47.9 (11.0) 48.7 (10.6) MDD 22.6 (3.3)a 22.9 (3.5)a Yes Outpatient TRD 
Paillère-Martinot et al., 2010 18 (11) 14 (10) 48.2 (7.8) 46.6 (10.3) Mixed 26.0 (6.4)b 25.9 (6.7)b Yes Inpatient TRD 
Speer et al., 20142 8 (5) 8 (11) 41.3 (14.5) 44.9 (9.1) Mixed 35.8 (10.6)e 24.0 (4.6)e No Mixed TRD 
Su et al., 20055 20 (15) 10 (7) 43.4 (11.3) 42.6 (11.0) Mixed 24.9 (6.4)b 22.7 (4.7)b Yes NR TRD 
Taylor et al., 2018 16 (11) 16 (10) 46.9 (10.7) 44.13 (11.1) MDD 16 (3.9)a 13.1 (2.3)a Yes Outpatient TRD 
Theleritis et al., 2017 (1)6 26 (15) 20 (10) 39.1 (10.1) 38.0 (9.9) MDD 30.6 (3.2)a 29.4 (3.2)a Yes Outpatient TRD 
Theleritis et al., 2017 (2)6 26 (11) 24 (10) 38.9 (13.9) 39.4 (8.9) MDD 29.7 (4.6)a 30.3 (3.6)a Yes Outpatient TRD 
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Zheng et al., 2010 19 (7) 15 (5) 26.9 (6.2) 26.7 (4.3) MDD 24.6 (3.0)a 24.6 (2.8)a Yes NR TRD 
LF-R 
Fitzgerald et al., 2003 (2) 20 (7) 20 (11) 45.6 (11.5) 49.2 (14.2) Mixed 37.7 (8.4)M 35.7 (8.1)M No Outpatient TRD 
Januel et al., 20062 11 (9) 16 (12) 38.6 (11.2) 37.2 (11.7) MDD 21.7 (3.5)a 22.5 (2.7)a Yes Inpatient non-TRD 
Pallanti et al., 2010 (1) 20 (12) 20 (12) 51.2 (12.5) 47.9 (9.1) MDD 28.0 (5.9)a 29.1 (3.5)a Yes Outpatient TRD 
LF-L 
Kimbrell et al., 1999 (2)2 5 (4) 3 (1) 44 (15.92) 43.67 (19.14) Mixed 34.4 (7.99)b 24.33 (6.81)b No Mixed TRD 
Padberg et al., 1999 6 (5) 6 (4) 46.7 (14.7) 43.3 (11.6) MDD 26.7 (9.4)b 22.2 (8.8)b NR NR TRD 
Speer et al., 2014 8 (5) 8 (3) 39.6 (9) 44.9 (9.1) Mixed 28.6 (7.6)e 24 (4.6)e No Mixed TRD 
BL 
Fitzgerald et al., 20062 25 (15) 25 (16) 46.8 (10.7) 43.7 (10.2) Mixed 22.5 (7.4)a 19.8 (4.4)a No Outpatient TRD 
Fitzgerald et al., 20167 23 (13) 23 (13) 46.3 (12.6) 49.7 (11.0) BD 23.2 (4.0)a 23.0 (5.1)a NA Outpatient TRD 
Fitzgerald et al., 2012 (2)2 22 (14) 20 (8) 40.5 (15.5) 44.9 (15.7) MDD 24.3 (3.6)a 22.8 (2.1)a No NR TRD 
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McDonald et al., 20068 50 (27) 12 (5) NR NR Mixed 26.4 (1.38)b 27.33 (2.86)b Yes Outpatient TRD 
Pallanti et al., 2010 (2) 20 (11) 20 (12) 47.6 (12.3) 47.9 (9.1) MDD 28.8 (6.0)a 29.1 (3.5)a Yes Outpatient TRD 
Prasser et al., 2015 (1) 17 (8) 17 (9) 50.4 (9.9) 42.6 (12.4) Mixed 25.0 (4.4)b 25.3 (5.4)b No Mixed Mixed 
iTBS 
Duprat et al., 2016 22 (16) 25 (17) 40.09 (11.45) 43.16 (12.15) MDD 21.14 (4.99)a 21.52 (6.21)a Yes Mixed TRD 
Li et al., 2014 (1) 15 (8) 15 (11) 42.4 (NR) 46.9 (NR) MDD 23.1 (3.9)a 23.8 (3.2)a Yes NR TRD 
cTBS 
Li et al., 2014 (2) 15 (10) 15 (11) 49.2 (NR) 46.9 (NR) MDD 24.3 (5.5)a 23.8 (3.2)a Yes NR TRD 
BLTBS 
Li et al., 2014 (3) 15 (11) 15 (11) 42.5 (NR) 46.9 (NR) MDD 25.4 (5.1)a 23.8 (3.2)a Yes NR TRD 
Prasser et al., 2015 (2) 20 (10) 17 (9) 48.2 (10.9) 42.6 (12.4) Mixed 27.4 (6.5)b 25.3 (5.4)b No Mixed Mixed 
dTMS 
Levkovitz et al..20156 101 (48) 111 (53) 45.1 (11.7) 47.6 (11.6) MDD 23.5 (4.3)b 23.4 (3.7)b Yes Outpatient TRD 
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Tavares et al., 20176 25 (17) 25 (18) 43.5 (12) 41.2 (8.9) BD 25.32 (3.76)a 25.8 (5.25)a NA Outpatient TRD 
sTMS 
Jin et al., 20146,9,10 29 (16) 16 (9) 42.5 (15.0) 46.3 (12.7) MDD 21.3 (4.0)a 19.4 (4.1)a No Outpatient non-TRD 
Leuchter et al., 2015 59 (NR) 61 (NR) 46.7 (11.2) 45.7 (12.6) MDD 21.8 (3.8)a 21.2 (2.9)a Yes Mixed Mixed 
Note. Mean ages are reported in years with standard deviation in parentheses for each of the active and sham treatment arms. The mean Hamilton Depression Rating Scale (HDRS) score at 
baseline is reported for each study with standard deviation in parentheses (except for Concerto et al., 2015 and Hansen et al., 2004 for which median, first quartile, and third quartile are 
reported). The Montgomery-Åsberg Depression Rating Scale (MADRS) score, denoted with superscript M, is reported when the HDRS was not recorded.  Means and standard deviations are 
rounded to the first figure after the decimal. Status refers to whether patients were outpatients, inpatients in a hospital admission, or whether there were both outpatients and inpatients (mixed). 
TMS = transcranial magnetic stimulation; HF-L = high-frequency left-sided repetitive transcranial magnetic stimulation; LF-R = low-frequency right-sided repetitive transcranial magnetic 
stimulation; BL = bilateral repetitive transcranial magnetic stimulation; iTBS = intermittent theta burst stimulation; cTBS = continuous theta burst stimulation; BLTBS = bilateral theta burst 
stimulation; dTMS = deep transcranial magnetic stimulation; sTMS = synchronised transcranial magnetic stimulation; NR = not reported; NA = not applicable; MDD = major depressive 
disorder; BD = bipolar depression; TRD = treatment resistant depression. 1MADRS based on the intention-to-treat sample who received ≥ 1 session of active stimulation. 2Numbers are based 
on the intention-to-treat sample. 3,4,5,8,9Two active treatment groups were combined. 6Numbers based on the intention-to-treat sample who received ≥ 1 session of active stimulation. 7HDRS 
based on the intention-to-treat sample. 10Age based on the intention-to-treat sample who received ≥ 1 session of active stimulation. 11Age based on 11 patients. 12Two patients had mixed 
features. 13Indicates Median and IQR. aHDRS-17. bHDRS-21. cHDRS-25. dHDRS-24. eHDRS-28. 
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Table 3 
Treatment characteristics: tDCS studies 
Authors Location 
Electrode 
size 
Current 
strength 
Current 
density 
Session 
duration 
Number of 
sessions 
Treatment 
strategy 
Sham 
stimulation 
 Anode Cathode/Reference        
Fregni et al., 2006a F3 FP2 35cm2 1mA 0.028 20min 5 Monotherapy 05sec 
Fregni et al., 2006b F3 FP2 35cm2 1mA 0.028 20min 5 Monotherapy 05sec 
Boggio et al., 20081 F3 FP2; Midline 35cm2 2mA 0.057 20min 10 Monotherapy 30sec 
Loo et al., 2010 pF3 F8 35cm2 1mA 0.028 20min 5 Mixed 30sec 
Blumberger et al., 2012 F3 F4 35cm2 2mA 0.057 20min 15 Mixed 30sec 
Brunoni et al., 20132 F3 F4 25cm2 2mA 0.080 30min 12 Monotherapy 60sec 
Salehinejad et al., 2015 F3 F4 35cm2 2mA 0.057 20min 22 Monotherapy 30sec 
Salehinejad et al., 2017 F3 F4 35cm2 2mA 0.057 30min 10 Monotherapy 30sec 
Brunoni et al., 20172 F3 F4 25cm2 2mA 0.080 30min 10 Monotherapy 30sec 
Sampaio-Junior et al., 2017 F33 F43 35cm2 2mA 0.080 30min 12 Augmentation 30sec 
Note. Electrode locations are reported according to the EEG 10/20 system. Current densities are reported in mA/cm2. Sham stimulation indicates the duration of time that current was 
applied for giving an initial sensation of tDCS on the scalp. tDCS = transcranial direct current stimulation. 1Two sham treatment groups were combined.2Patients in sham group also 
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received an oral placebo tablet.3Omnilateral electrode system. 
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Table 4 
Sample characteristics: tDCS studies 
Authors 
Number of participants 
(female) 
Age Diagnosis HDRS 
Excluded 
psychosis 
Status 
Treatment 
resistance 
 Active Sham Active Sham  Active Sham    
Fregni et al., 2006a 5 (NR) 5 (NR) NR NR MDD NR NR NR NR NR 
Fregni et al., 2006b 9 (5) 9 (6) 47.6 (10.4) 45.3 (9.3) MDD 23,6 (5,0) 25,9 (4,3) Yesa Outpatient NR 
Boggio et al., 20081 21 (14) 19 (13) 51.6 (7.7) 46.4 (7.1) MDD 21,1 (4,4)b 21,8 (4,8)b Yes NR Mixed 
Loo et al., 20102 20 (11) 20 (11) 49.0 (10.0) 45.6 (12.5) MDD 18,3 (5,8)c 17,3 (4,7)c Yesa Outpatient Mixed 
Blumberger et al., 20123,6 13 (10) 11 (10) 45.3 (11.6) 49.7 (9.4) MDD 24,9 (3,1)c 24,1 (2,9)c Yes Outpatient TRD 
Brunoni et al., 20134 30 (21) 30 (20) 41.0 (12.0) 46.4 (14.0) MDD 21,0 (3,8)c 22,0 (4,2)c Yes Outpatient Mixed 
Salehinejad et al., 2015 15 (8) 15 (9) 28.7 (5.87) 27.9 (5.84) MDD 24.7 (3.05)d 22.8 (2.06)d Yes Outpatient TRD 
Salehinejad et al., 2017 12 (7) 12 (8) 26.8 (7.1) 25.5 (4.6) MDD 24,6 (2,6)d 22,6 (1,9)d Yes Outpatient non-TRD 
Brunoni et al., 20175,6,7 91 (64) 60 (41) 44 (11.19) 40.88 (12.87) MDD 21.93 (3.89)c 22.7 (4.27)c Yes Outpatient Mixed 
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Sampaio-Junior et al., 20178 30 (16) 29 (24) 46.2 (11.8) 45.7 (10.3) BD 23.1 (3.9) 23.5 (4.7) NA Outpatient Mixed 
Note. Mean ages are reported in years with standard deviation in parentheses for each of the active and sham treatment arms. The mean Hamilton Depression Rating Scale (HDRS) 
score at baseline is reported for each study with standard deviation in parentheses. Means and standard deviations are rounded to the first figure after the decimal. Status refers to 
whether patients were outpatients, inpatients in a hospital admission, or whether there were both outpatients and inpatients (mixed). tDCS = transcranial direct current stimulation; 
MDD = major depressive disorder; TRD = treatment resistant depression; NR = not reported; NA = not applicable. 1Two sham treatment groups were combined. 2,3,4,7,8Numbers are 
based on the intention-to-treat sample.5Numbers based on participants of age ≤ 70 years.6Patients in sham group also received an oral placebo tablet. aExcluded “other psychiatric 
disorders.” bHDRS-21. cHDRS-17. dHDRS-24. 
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Table 5 
Random-Effects Meta-Analysis of Response Rates 
Treatment Modality k Odds Ratio 95% Confidence Interval Q I2 
HF-L 32 3.75 2.44 5.75 41.96 26.1% 
LF-R 3 7.44 2.06 26.83 1.59 0.0% 
LF-L 3 1.41 0.15 12.88 0.14 0.0% 
BL 6 3.68 1.66 8.13 3.45 0.0% 
cTBS* 1 1.63 0.23 11.46 - - 
iTBS 2 4.70 1.14 19.38 0.02 0.0% 
blTBS 2 4.28 0.54 34.27 2.91 65.7% 
dTMS 2 1.69 1.003 2.85 0.97 0.0% 
sTMS 2 2.71 0.44 16.86 4.15 75.9% 
tDCS 9 4.17 2.25 7.74 10.83 26.2% 
Note. HF-L = high-frequency, left-sided repetitive transcranial magnetic stimulation; LF-R 
= low-frequency, right-sided repetitive transcranial magnetic stimulation; LF-L = low-
frequency, left-sided repetitive transcranial magnetic stimulation; BL = bilateral repetitive 
transcranial magnetic stimulation; dTMS = deep transcranial magnetic stimulation; cTBS = 
continuous theta burst stimulation; iTBS = intermittent theta burst stimulation; blTBS = 
bilateral theta burst stimulation; sTMS = synchronised transcranial magnetic stimulation; 
tDCS = transcranial magnetic stimulation. *inverse variance method used. 
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Table 6 
Random-Effects Meta-Analysis of Remission Rates 
Treatment Modality k Odds Ratio 95% Confidence Interval Q I2 
HF-L 26 2.52 1.62 3.89 25.35 1.4% 
LF-R 2 14.10 2.79 71.42 0.50 0.0% 
LF-L 3 0.86 0.08 9.11 0.03 0.0% 
BL 5 3.05 0.87 10.67 4.48 10.7% 
cTBS - - - - - - 
iTBS* 1 6.22 0.28 136.90 - - 
blTBS* 1 1.32 0.19 9.02 - - 
dTMS 2 2.24 1.24 4.06 0.02 0.0% 
sTMS 2 2.51 0.23 26.76 4.12 75.7% 
tDCS 8 2.88 1.65 5.04 6.32 0.0% 
Note. HF-L = high-frequency, left-sided repetitive transcranial magnetic stimulation; LF-R 
= low-frequency, right-sided repetitive transcranial magnetic stimulation; LF-L = low-
frequency, left-sided repetitive transcranial magnetic stimulation; BL = bilateral repetitive 
transcranial magnetic stimulation; dTMS = deep transcranial magnetic stimulation; cTBS = 
continuous theta burst stimulation; iTBS = intermittent theta burst stimulation; blTBS = 
bilateral theta burst stimulation; sTMS = synchronised transcranial magnetic stimulation; 
tDCS = transcranial magnetic stimulation. *inverse variance method used. 
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Table 7 
Random-Effects Meta-Analysis of Continuous Treatment Effects 
Treatment Modality k g 95% Confidence Interval Q I2 
HF-L 29 -0.72 -0.99 -0.46 102.67 72.7% 
LF-R 2 -0.77 -1.64 0.09 2.72 63.3% 
LF-L 2 -0.33 -1.18 0.51 0.76 0.0% 
BL 4 -0.07 -0.38 0.25 0.25 0.0% 
cTBS - - - - - - 
iTBS 1 -0.44 -1.02 0.14 0.00 - 
blTBS 1 -0.03 -0.65 0.56 - - 
dTMS 2 -0.29 -0.55 -0.03 0.75 0.0% 
sTMS 2 -0.55 -1.13 0.02 3.24 69.1% 
tDCS 7 -0.76 -1.31 -0.21 33.68 82.2% 
Note. HF-L = high-frequency, left-sided repetitive transcranial magnetic stimulation; LF-R 
= low-frequency, right-sided repetitive transcranial magnetic stimulation; LF-L = low-
frequency, left-sided repetitive transcranial magnetic stimulation; BL = bilateral repetitive 
transcranial magnetic stimulation; dTMS = deep transcranial magnetic stimulation; cTBS = 
continuous theta burst stimulation; iTBS = intermittent theta burst stimulation; blTBS = 
bilateral theta burst stimulation; sTMS = synchronised transcranial magnetic stimulation; 
tDCS = transcranial direct current stimulation. *inverse variance method used. 
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Table 8 
Random-Effects Meta-Analysis of All-cause Discontinuation Rates 
Treatment Modality k Odds Ratio 95% Confidence Interval Q I2 
HF-L 35 0.86 0.60 1.23 14.58 0.0% 
LF-R 3 0.48 0.12 1.99 0.35 0.0% 
LF-L 3 0.84 0.11 6.73 0.71 0.0% 
BL 6 0.90 0.33 2.43 3.03 0.0% 
cTBS* 1 1.00 0.02 53.66 - - 
iTBS 2 1.06 0.06 17.66 0.00 0.0% 
BLTBS 2 0.47 0.04 5.88 0.23 0.0% 
dTMS 2 1.03 0.32 3.36 2.10 52.3% 
sTMS 2 0.72 0.36 1.44 0.32 0.0% 
tDCS 10 1.34 0.71 2.52 6.66 0.0% 
Note. HF-L = high-frequency, left-sided repetitive transcranial magnetic stimulation; LF-R 
= low-frequency, right-sided repetitive transcranial magnetic stimulation; LF-L = low-
frequency, left-sided repetitive transcranial magnetic stimulation; BL = bilateral repetitive 
transcranial magnetic stimulation; dTMS = deep transcranial magnetic stimulation; cTBS = 
continuous theta burst stimulation; iTBS = intermittent theta burst stimulation; blTBS = 
bilateral theta burst stimulation; sTMS = synchronised transcranial magnetic stimulation; 
tDCS = transcranial direct current stimulation. *inverse variance method used. 
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Supplementary Figure 1. Contour-enhanced funnel plot of all RCTs included in the meta-analysis of 
remission rates. 
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Supplementary Figure 2. Contour-enhanced funnel plot of all RCTs included in the meta-analysis of 
post-treatment continuous depression scores. 
 
  
−3 −2 −1 0 1
1.
0
0.
8
0.
6
0.
4
0.
2
0.
0
Standardised Mean Difference
S
ta
nd
ar
d 
E
rr
or
0.1 < p < 0.05
0.05 < p < 0.01
p < 0.01
4. Risk of bias assessment 
 
Supplementary Table 1. Cochrane risk of bias tool. 
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Garcia- Toro et al., 2001 Unclear Unclear Unclear Low Low Low Unclear 
George et al., 1997 Unclear Unclear Unclear Low Low Unclear Unclear 
George et al., 2000 Unclear Unclear Low Low Low Low Unclear 
George et al., 2010 Low Unclear Low Low Low Low Low 
Hansen et al., 2004 Low Unclear Low Low High Low High 
Hernandez- Ribas et al., 2013 Unclear Unclear Unclear Low Low Low Unclear 
Holtzheimer et al., 2004 Unclear Unclear Unclear Low Low Low Unclear 
Jakob et al., 2008 Unclear Unclear Unclear Unclear  Low Low Unclear 
Januel et al., 2006 Unclear Unclear Unclear Low Low Low Unclear 
Jin and Phillips, 2014 Low Unclear Low Unclear  Low Low Unclear 
Kimbrell et al., 1999 Unclear Unclear Unclear Low Low Low Unclear 
Kreuzer et al., 2015 Low Unclear Low Low High Low High 
Leuchter et al., 2015 Low Unclear Low Low Low Low Low 
Levokovitz et al., 2015 Low Low  Low Low Low Low Low 
Li et al., 2014 Unclear Unclear Unclear Low Low Low Unclear 
Lingeswaran et al., 2011 Low Low  Low Low Unclear Low Unclear 
Loo et al., 1999 Unclear Unclear Low Low Low Low Unclear 
Loo et al., 2007 Low Unclear Low Low Low Low Low 
McDonald et al., 2006 Unclear Unclear Unclear Low Low Low Unclear 
Mogg etal., 2008 Low Low  High High Low Low High 
Nahas et al., 2003 Low Unclear Low Low Low Low Low 
O'Reardon et al., 2007 Unclear Unclear Unclear Low Low Low Unclear 
Padberg et al., 1999 Unclear Unclear Unclear Low Low Low Unclear 
Paillere-Martinot et al., 2010 Low Low  Low Low Low Low Low 
Pallanti et al., 2010 Low Low  Unclear Low Low Low Unclear 
Prasser et al., 2015 Unclear Unclear Unclear Low Low Low Unclear 
Speer et al., 2014 Unclear Unclear Unclear Low Low Low Unclear 
Su et al., 2005 Unclear Unclear Unclear Low Low Low Unclear 
Tavares et al., 2017 Low Low  Low Low Low Low Low 
Taylor et al., 2018 Low Low  High Low  High Low High 
Theleritis et al., 2017 Low Low  Low Low Low Low Low 
Zheng et al., 2010 Unclear Unclear Unclear Unclear  Low Low Unclear 
  
5. Sensitivity analyses – response rates. 
 
Supplementary Figure 3a. Forest plot of HF-L (diagnosis). 
 
Supplementary Figure 3b. Forest plot of HF-L (exclusion psychosis). 
 
Supplementary Figure 3c. Forest plot of HF-L (hospitalisation status). 
 
Supplementary Figure 3d. Forest plot of HF-L (treatment resistance). 
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Supplementary Figure 4a. Forest plot of BL (diagnosis). 
 
 
Supplementary Figure 4b. Forest plot of BL (exclusion psychosis). 
 
 
Supplementary Figure 5. Forest plot of tDCS (treatment resistance). 
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6. Sensitivity analyses – remission rates. 
	
Supplementary Figure 6a. Forest plot of HF-L (diagnosis). 
	
Supplementary Figure 6b. Forest plot of HF-L (exclusion psychosis). 
	
Supplementary Figure 6c. Forest plot of HF-L (hospitalisation status). 
	
Supplementary Figure 6d. Forest plot of HF-L (treatment resistance). 
	
Supplementary Figure 7a. Forest plot of BL (diagnosis). 
	
 
Diagnosis
BD
MDD
Mixed
   n
   1
 68
 38
   Active
    N
  11
538
185
  n
  1
24
  5
  Sham
   N
  12
509
148
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
1.10
2.55
3.54
95%−CI
[0.06;  20.01]
[1.37;    4.74]
[1.54;    8.15]
Excluded psychosis
No
Yes
   n
 16
 90
   Active
    N
165
534
  n
  5
24
  Sham
   N
149
484
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
1.85
3.67
95%−CI
[0.72;   4.75]
[1.91;   7.07]
Hospitalisation status
Inpatients
Mixed
Outpatients
  n
16
  2
62
  Active
   N
  62
  51
457
  n
  5
  0
24
  Sham
   N
  50
  55
422
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
2.50
1.92
2.34
95%−CI
[0.71;    8.74]
[0.37;  10.06]
[1.21;    4.51]
Treatment resistance
Mixed
non−TRD
TRD
   n
   4
   1
 96
   Active
   N
  31
  12
625
  n
  1
  0
25
  Sham
   N
  24
  10
566
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
7.43
1.74
3.04
95%−CI
[0.69;  79.96]
[0.13;  23.71]
[1.72;    5.37]
Diagnosis
BD
MDD
Mixed
  n
  2
  2
15
Active
  N
 23
 39
 92
 n
 0
 1
 2
Sham
  N
23
37
54
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
5.47
2.11
3.51
95%−CI
[0.25; 120.37]
[0.18;   25.35]
[0.37;   33.23]
Supplementary Figure 7b. Forest plot of BL (exclusion psychosis). 
	
 
Supplementary Figure 8. Forest plot of tDCS (treatment resistance). 
	 	
Excluded psychosis
No
Yes
  n
12
  5
Active
  N
 61
 70
 n
 2
 1
Sham
 N
59
32
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
5.13
2.00
95%−CI
[0.13; 197.49]
[0.29;   13.65]
Treatment resistance
Mixed
non−TRD
TRD
  n
51
  3
  8
  Active
   N
191
  12
  28
  n
19
  0
  0
  Sham
   N
158
  12
  26
0.01 0.1 0.5 1 2 10 200
Odds Ratio
Favours sham treatment Favours active treatment
OR
2.58
9.21
6.99
95%−CI
[1.44;     4.63]
[0.42; 200.59]
[0.18; 265.96]
7. Reasons for excluding full-texts 
	
Did not meet age criteria 
Beynel et al., 2014 
Blumberger et al., 2012 
Chistyakov et al., 2015 
Dolberg et al., 2002 
Garcia-Toro et al., 2006 
He et al., 2011 
Höppner et al., 2003 
Kang et al., 2016 
Kauffmann et al., 2004 
Klein et al., 1999 
Koerselman et al., 2004 
Loo et al., 2003 
Loo et al., 2007 
Loo et al., 2012 
Loo et al., 2017 
Manes et al., 2001 
Miniussi et al., 2005 
Mogg et al., 2008 
Mosimann et al., 2004 
Nadeau et al., 2014 
Padberg et al., 2002 
Palm et al., 2012 
Plewnia et al., 2014 
Rossini et al., 2005 
Stern et al., 2007 
Triggs et al., 2010 
Different stimulation technique 
Barclay & Barclay, 2014 
Carpenter et al., 2017 
Fang et al., 2016 
Martiny et al., 2010 
McClure et al., 2015 
Rong et al., 2012 
Schutter et al., 2009 
Shiozawa et al., 2015 
Did not present data on depressive symptoms 
Aguirre et al., 2011 
Boggio et al., 2007 
Grisaru et al., 1998 
Kozel et al., 2011 
Minichino et al., 2014 
Möller et al., 2006 
Nejati et al., 2017 
Pascual-Leone et al., 1996 
Praharaj et al., 2009 
Schutter & Koerselman, 2012 
Speer et al., 2009 
Speer et al., 2001 
Szuba et al., 2001 
Presented duplicate data 
Baeken et al., 2015 
Baeken et al., 2014 
Dang et al., 2007 
Hausmann et al., 2004 
Herbsman et al., 2009 
Lisanby et al., 2009 
Loo et al., 2001 
Nahas et al., 2001 
Powell et al., 2014 
Rosenquist et al., 2013 
Schutter et al., 2010 
Solvason et al., 2014 
Ullrich et al., 2013 
Co-initiation of medication 
Bennabi et al., 2015 
Hausmann et al., 2004 
Herwig et al., 2007 
Herwig et al., 2003 
Hoeppner et al., 2010 
Peng et al., 2012 
Ray et al., 2011 
Ullrich et al., 2012 
Zheng et al., 2015 
Co-initiation of CCT 
Brunoni et al., 2014 
Segrave et al., 2014 
Vanderhasselt et al., 2015 
Co-initiation of sleep deprivation 
Krstic et al., 2014 
Did not include a sham condition* 
Arns et al., 2010 
Chistyakov et al., 2010 
Fujita & Koga, 2005 
Janicak et al., 2010 
Kolbinger et al., 1995 
Kuroda et al., 2006 
Levkovitz et al., 2009 
Nongpiur et al., 2011 
Rybak et al., 2005 
Schrijvers et al., 2012 
Tamas et al., 2007 
Vanderhasselt et al., 2009 
Vanderhasselt et al., 2016 
Woźniak-Kwaśniewska et al., 2015 
Case report 
Cohen et al., 2008 
Vedeniapin et al., 2010 
Editorial 
Lisanby, 2003 
Study protocol 
Pereira Junior et al., 2015 
Depression not primary diagnosis 
Carretero et al., 2009 
Note. Full-text articles excluded. *for cross-over trials that included a sham condition, data were not 
available separately for the active and sham conditions prior to the cross-over. 
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TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
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participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
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